As Cost Climbs 30%, Dermatology Drug Bills Get Under Plans’ Skin
The Navitus 2025 Drug Trend Report found that dermatology specialty drug spending in commercial health plans increased 30.3%, reaching $6.03 per member per month across skin condition treatments. This growth was driven primarily by increased utilization, particularly of drugs like Dupixent, as coverage expands and prescribing rises.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
CLARITY FOR ACTION
Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download
Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.
Related blogs
Navigating Healthcare and Improving Outcomes
PBM 101: Demystifying the Complex World of Specialty Drugs
Unless you work in the pharmacy benefit management (PBM) industry, it’s easy to assume that a “specialty drug” is simply a more expensive prescription. In reality, specialty medications sit in a separate category, with different rules and far bigger consequences…
